Evaluation of NKX2-2 Expression in Round Cell Sarcomas and Other Tumors with EWSR1 Rearrangement: Imperfect Specificity for Ewing Sarcoma
Overview
Affiliations
Ewing sarcoma shows considerable histologic overlap with other round cell tumors. NKX2-2, a homeodomain transcription factor involved in neuroendocrine/glial differentiation and a downstream target of EWSR1-FLI1, has been reported as an immunohistochemical marker for Ewing sarcoma. We assessed the specificity of NKX2-2 for Ewing sarcoma compared with other round cell malignant neoplasms and other soft tissue tumors with EWSR1 translocations. We evaluated whole-tissue sections from 270 cases: 40 Ewing sarcomas (4 with atypical/large cell features), 20 CIC-DUX4 sarcomas, 5 BCOR-CCNB3 sarcomas, 9 unclassified round cell sarcomas, 10 poorly differentiated synovial sarcomas, 10 lymphoblastic lymphomas, 10 alveolar rhabdomyosarcomas, 10 embryonal rhabdomyosarcomas, 10 Merkel cell carcinomas, 10 small cell carcinomas, 20 melanomas, 5 NUT midline carcinomas, 10 Wilms tumors, 10 neuroblastomas, 10 olfactory neuroblastomas, 12 mesenchymal chondrosarcomas, 10 angiomatoid fibrous histiocytomas, 10 clear cell sarcomas, 5 gastrointestinal clear cell sarcoma-like tumors, 5 desmoplastic small round cell tumors, 10 extraskeletal myxoid chondrosarcomas, 10 soft tissue and cutaneous myoepitheliomas, and 19 myoepithelial carcinomas. NKX2-2 positivity was defined as moderate-to-strong nuclear immunoreactivity in at least 5% of cells. NKX2-2 was positive in 37/40 (93%) Ewing sarcomas, including all atypical Ewing sarcomas and cases with known EWSR1-FLI1 or EWSR1-ERG fusion; 85% of Ewing sarcomas showed diffuse (>50%) staining. NKX2-2 was positive in 9 (75%) mesenchymal chondrosarcomas, 8 (80%) olfactory neuroblastomas, 1 CIC-DUX4 sarcoma, 1 poorly differentiated synovial sarcoma, 1 neuroblastoma, 2 unclassified round cell sarcomas, and 3 small cell carcinomas; all other EWSR1-associated tumors were negative for NKX2-2, apart from 1 desmoplastic small round cell tumor, 1 myoepithelioma, and 1 myoepithelial carcinoma. In summary, NKX2-2 is a sensitive but imperfectly specific marker for Ewing sarcoma. Nonetheless, NKX2-2 may be helpful to distinguish Ewing sarcoma from some histologic mimics including CIC-DUX4 and BCOR-CCNB3 sarcomas. Most other EWSR1-associated soft tissue tumors are negative for NKX2-2.
Giner F, Medina-Ceballos E, Lopez-Reig R, Machado I, Lopez-Guerrero J, Navarro S Int J Mol Sci. 2024; 25(14).
PMID: 39062853 PMC: 11276717. DOI: 10.3390/ijms25147615.
Shiyanbola O, Nigdelioglu R, Dhall D, Gonzalez I, Warmke L, Schechter S Am J Surg Pathol. 2024; 48(9):1185-1194.
PMID: 38767576 PMC: 11321603. DOI: 10.1097/PAS.0000000000002236.
Expression of NKX2.2 in Non-Ewing Tumors With Round Cell Morphology.
Saeed S, Hassan U, Hussain M, Mushtaq S, Ishtiaq S Cureus. 2024; 15(12):e50704.
PMID: 38234938 PMC: 10792351. DOI: 10.7759/cureus.50704.
Machado I, Agaimy A, Giner F, Navarro S, Michal M, Bridge J Virchows Arch. 2023; 484(5):765-775.
PMID: 37940743 PMC: 11694230. DOI: 10.1007/s00428-023-03687-3.
Yasir M, Park J, Chun W Int J Mol Sci. 2023; 24(20).
PMID: 37894854 PMC: 10607184. DOI: 10.3390/ijms242015173.